Professor

Director of Clinical Trial Center, Director of Pharmacy Department,

Peking University First Hospital

Research Areas

Clinical Pharmacology

Clinical Pharmacy

Education & Positions

Beijing Medical School, Pharmacy, Bachelor Degree, 1986-1991

Beijing Medical School, Pharmacy, Master Degree, 1996-1998

Jichi Medical School, Clinical Pharmacology, MD & PhD, 2001-2003

Chief Pharmacist, Peking University First Hospital, 2006-

Director, Pharmacy Department, Peking University First Hospital, 2007-

Professor, Peking University First Hospital, 2009-

Director, Clinical Trial Center, Peking University First Hospital, 2017-

Faculty Accolades

Science and Technology Award of Chinese Pharmaceutical Association, second prize, 2012

Huaxia Medical Science and Technology Award, Third prize, 2013

China Pharmaceutical Development Award, Innovation Drugs Award, Outstanding Achievement Award, 2013

WuXi PharmaTech Presents Life Science and Chemistry Award,Scholar Award, 2017

Zijing Award for Pharmacists, China Health Promotion Foundation, 2018

Research Interests:

Professor Cui has been engaged in study of early phase clinical trials of innovative drugs，policy of national drug evaluation and new drug approval for more than 15 years. He led the team to establish technology platform focused on pharmacogenomics, clinical pharmacy and drug clinical trials thereby providing support for clinical rational medication and precision medicine. He has hosted over 100 clinical trials as a primary investigator and has participated in the administration of more than 1000 clinical trials in total. Cardiovascular and cerebrovascular drugs, especially antithrombotic drugs are the priority research areas of interests. The team has been awarded several grants from Chinese government including National Key Project of Research and Development Plan, ‘Significant New Drug Development’ of National Science and Technology Major Project and National Natural Science Foundation of China. Professor Cui has published more than 300 papers (including nearly 70 SCIs) and the cumulative Impact Factor was more than 200 points.

Grants and fundings

• National Key R&D Program of China, No.2016YFC0904900, Principal Investigator, 2016.7-2018.12 (￥53530000: ￥9530000 from the government)
• ‘Significant New Drug Development’ of National Science and Technology Major Project, No. 2012ZX09303005-003, Principal Investigator of subproject, 2011.1-2016.12 (￥900000)
• ‘Significant New Drug Development’ of National Science and Technology Major Project, No.2009ZX09501-032, Principal Investigator of subproject, 2009.1-2010.12 (￥574000)
• ‘Significant New Drug Development’ of National Science and Technology Major Project, No.2008ZX09312-017, Principal Investigator of subproject, 2008.1-2012.12 (￥1890000)
• National Natural Science Foundation of PR China, No. 81573504, Principal Investigator, 2016.1-2019.12 (￥720000)
• National Natural Science Foundation of PR China, No. 81273592, Principal Investigator, 2013.1-2016.12 (￥700000)
• National Natural Science Foundation of PR China, No. 81072704, Principal Investigator, 2011.1-2011.12 (￥100000)
• Municipal Natural Science Foundation of Beijing, No.7171012, Principal Investigator, 2017.1-2020.12 (￥800000)

Publications

1. Fan H, Li C1, Xiang Q, Xu L, Zhang Z, Liu Q, Zhang T, Zhou Y, Zhao X, Cui Y*.  PIK3CA mutations and response for neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis. Thorac Cancer, 2018, 9(5):571-579.
2. Ying Zhang, Lan Miao, Li Lin, Chang-Ying Ren, Jian-Xun Liu*, Yi-Min Cui*. Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats. Phytomedicine, 2018, 38(15):125-134.  
3. Qian Xiang, Shuang Zhou, Joshua P. Lewis, Alan R. Shuldiner, Guanhua Ren, Yimin Cui*. Genetic variants of PEAR1 are associated with platelet function and efficacy of antiplatelet drugs: systematic review and meta-analysis. Current Pharmaceutical Design, 2017, 23(44):6815-6827.
4. Yitong Wang, Bingfeng Xu, Lixia Zhu, Kun Lou, Yingli Chen, Xia Zhao, Qian Wang, Ling Xu, Xiaohui Guo, Linong Ji, Yimin Cui*, Yi Fang*. Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2017, 37(12):1107-1115.
5. Sheng XY, Chen CY, Ma LY, Liu YO, Zhou Y, Cui YM*. Population pharmacokinetics of vancomycin in Chinese infants, International Journal of Clinical Pharmacology and Therapeutics, 2017, 55(7):558-566.
6. Chen CY,Li X,Ma LY,Wu PH,Zhou Y,Feng Q,Cui YM*. In Utero Oxcarbazepine Exposure and Neonatal Abstinence Syndrome: Case Report and Brief Review of the Literature. Pharmacotherapy, 2017,37(7):e71-e75.
7. Min Lu, Li-xia Zhu, Ji-Ling Yan, Ying-Zheng Wang, Xia Zhao, Ying Zhou, Yi-Min Cui*. Pharmacokinetics pharmacodynamics and tolerability of single dose of recombinant glucagon-like peptide-1 receptor agonist in healthy chinese subjects. International Journal of Clinical and Experimental Medicine, 2017,10(5): 8018-24.
8. Yang T , Liu Q, Lu M, Ma L, Zhou Y, Cui Y*.. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: A meta-analysis. British Journal of Clinical Pharmacology, 2017,83(7): 1369-1379.
9. Sun J, Xiang Q, Li C, Wang Z, Hu K, Xie Q, Cui Y*. Efficacy and safety of novel oral P2Y12 receptor inhibitors in ST-segment elevation myocardial infarction patients undergoing PCI: A systematic review and meta-analysis. Journal of Cardiovascular Pharmacology, 2017,69(4): 215-227.
10. Xiang Q, Li C, Zhao X, Cui YM*.The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. Journal of Clinical Pharmacy and Therapeutics, 2017,42(3):345-349.
11. Zhao X, Wang Z, Wang Y, Zhang H, Blode H, Yoshikawa K, Becker C, Unger S, Frey R, Cui Y*. Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study. Clinical Pharmacokinetics, 2016,55(5):615-624.
12. Xiang Q, Ji SD, Zhang Z, Zhao X, Cui YM*. Identification of ITGA2B and ITGB3 single-nucleotide polymorphisms and their influences on the platelet function. BioMed Research International, 2016;2016: 5675084.
13. Min Lu, Shiyi Lv, Sisi Xi, Xing Chen, Zhenfang Yuan, Yang Zhang, Wenpei Bai, Yimin Cui*. Progestin induced secondary diabetes mellitus and adrenal insufficiency: a case report. International Journal of Clinical & Experimental Medicine, 2016, 9 (10): 10778-10780.
14. Li C, Sun J, Xiang Q, Liang Y, Zhao N, Zhang Z, Liu Q, Cui Y*. Prognostic role of microRNA-21 expression in gliomas: a meta-analysis. Journal of Neuro-Oncology, 2016,130(1):1-7.
15. Zhou Y, Ma LY, Zhao X, Tian SH, Sun LY, Cui YM*. Impact of pharmacist intervention on antibiotic use and prophylactic antibiotic use in urology clean operations. Journal of Clinical Pharmacy and Therapeutics, 2015,40(4):404-408.
16. Zhao X, Cui Y*, Zhao S, Lang B, Broedl UC, Salsali A, Pinnetti S, Macha S. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics, 2015,37(7):1493-1502.
17. Yang T, Lu M, Ma L, Zhou Y, Cui Y*. Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.European Journal of Clinical Pharmacology, 2015, 71(11):1325-1332.
18. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, Tang G, Wang B, Chen D, He M, Fu J, Cai Y, Shi X, Zhang Y, Cui Y, Sun N, Li X, Cheng X, Wang J, Yang X, Yang T, Xiao C, Zhao G, Dong Q, Zhu D, Wang X, Ge J, Zhao L, Hu D, Liu L, Hou FF. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA, 2015, 313(13):1325-1335.